资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入构成为：耗材类77.55%，设备类18.25%，其他(补充)2.35%，其他1.85%。 12月1日，威高血净涨2.00%，成交额1.17亿元。两融数据显示，当日威高血净获融资买入额1226.45万 元，融资偿还1273.81万元，融资净买入-47.36万元。截至12月1日，威高血净融资融券余额合计1.53亿 元。 融资方面，威高血净当日融资买入1226.45万元。当前融资余额1.53亿元，占流通市值的9.42%。 融券方面，威高血净12月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 责任编辑：小浪快报 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-046 山东威高血液净化制品股份有限公司 2025年度"提质增效重回报"行动方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于 开展沪市公司"提质增效重回报"专项行动的倡议》，山东威高血液净化制品股份有限公司（以下简 称"公司"）结合自身实际经营情况、发展战略及财务状况，基于对未来持续稳定发展的信心和对公司价 值的认可，制定了《2025年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在持续优化经 营效率、完善公司治理、强化投资者回报，不断增强核心竞争力，推动公司高质量发展与投资价值提 升，切实保护投资者尤其是中小投资者的合法权益。本次行动方案已于2025年12月1日经公司第二届董 事会第十九次会议审议通过，具体内容如下： 一、聚焦主营业务，推动公司经营提质增效 登录新浪财经APP 搜索【信披】查看更多考评等级 公司始终专注于血液净化医用制品的研发、生产和销售， ...

证券代码：603014 证券简称：威高血净 公告编号：2025-046 山东威高血液净化制品股份有限公司 2025 年度"提质增效重回报"行动方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，山东 威高血液净化制品股份有限公司（以下简称"公司"）结合自身实际经营情况、发展 战略及财务状况，基于对未来持续稳定发展的信心和对公司价值的认可，制定了 《2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在持续优化 经营效率、完善公司治理、强化投资者回报，不断增强核心竞争力，推动公司高质 量发展与投资价值提升，切实保护投资者尤其是中小投资者的合法权益。本次行动 方案已于 2025 年 12 月 1 日经公司第二届董事会第十九次会议审议通过，具体内容 如下： 一、聚焦主营业务，推动公司经营提质增效 公司始终专注于血液净化医用制品的研发、生产和销售，主要产品血液透析器、 血液透析 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-048 山东威高血液净化制品股份有限公司 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于 2025 年度"提质增效重回报"行动方案的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司 2025 年度"提质增效重回 报"行动方案》。 表决结果：9 票同意，0 票弃权，0 票反对。 特此公告。 山东威高血液净化制品股份有限公司董事会 第二届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十九次会议于 2025 年 12 月 1 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 11 月 27 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席 ...

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

证券代码：603014 证券简称：威高血净 公告编号：2025-046 山东威高血液净化制品股份有限公司 关于发行股份购买资产暨关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 自本次交易预案披露以来，公司及相关各方积极推进本次交易的各项工作。截 至本公告披露日，本次交易涉及的审计、评估、尽职调查等工作正按照计划开展。 待相关工作完成后，公司将再次召开董事会审议本次交易的相关事项。 公司将根据本次交易工作的进展情况，严格按照《上市公司重大资产重组管理 办法》《上海证券交易所上市公司自律监管指引第 6 号——重大资产重组》等法律 法规和规范性文件的有关规定，及时履行信息披露义务。 四、风险提示 本次交易尚需公司董事会再次审议及公司股东会审议批准，并获得有权监管机 构批准、核准、注册或同意后方可正式实施；本次交易能否取得相关批准、核准、 注册或同意，以及最终取得的时间均存在不确定性，有关信息均以公司指定信息披 露媒体发布的公告为准。敬请广大投资者关注后续公告并理性投资，注意投资风险。 特此说明。 一、本次交易 ...

威高血净公告称，公司正筹划发行股份购买威高普瑞100%股权，预计构成重大资产重组和关联交易， 不构成重组上市。公司股票于2025年10月20日开市起停牌，11月3日开市起复牌。截至公告披露日，交 易涉及的审计、评估等工作正按计划开展，待完成后将再次召开董事会审议。本次交易尚需公司董事 会、股东会审议及监管机构批准，存在不确定性。 ...

Core Viewpoint - The company, Shandong Weigao Blood Purification Products Co., Ltd., is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% of Weigao Puri Pharmaceutical Packaging Co., Ltd. [2][3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [2][3][7] - The company was established on December 27, 2004, and went public on May 19, 2025 [3][7] - As of September 30, 2025, the company reported a revenue of 2.736 billion yuan, a year-on-year increase of 3.45%, and a net profit attributable to shareholders of 341 million yuan, up 7.92% year-on-year [7][8] Market Activity - On November 28, the stock price of Weigao Blood Purification increased by 1.13%, with a trading volume of 75.5524 million yuan and a turnover rate of 4.74%, bringing the total market capitalization to 16.890 billion yuan [1] - The company is categorized under the medical device sector, specifically focusing on medical consumables, with a revenue composition of 77.55% from consumables, 18.25% from equipment, and 2.35% from other sources [7] Strategic Initiatives - The company is focusing on expanding its international presence, particularly in Southeast Asia, South America, Eastern Europe, and North Africa, with subsidiaries already established in Ecuador and Indonesia [2] - The planned acquisition of Weigao Puri is expected to enhance the company's product offerings and market position, while not affecting the actual control of the company [3]

Core Insights - The "14th Five-Year Plan" period is identified as a golden opportunity for Weigao Blood Purification (603014) to achieve leapfrog development, focusing on domestic substitution breakthroughs, full industry chain construction, and key layouts for capital market entry [1][2] - Weigao Blood Purification successfully listed on the Shanghai Stock Exchange in May 2025, raising a net amount of 978 million yuan, marking it as one of the largest IPOs in the medical device sector this year, significantly enhancing the synergy between capital and industry for ongoing R&D and capacity expansion [1] - The company has established itself as a benchmark for domestic substitution in the blood dialysis consumables sector, leveraging policy opportunities for high-quality development and accelerated domestic substitution, leading to a dominant market share in blood dialysis consumables [1] Policy and Market Support - The national focus on key technologies for blood purification during the "14th Five-Year Plan" has provided crucial support for Weigao Blood Purification's development, with the establishment of special R&D funds and breakthroughs in critical technologies such as hollow fiber membranes [1] - The company has built a comprehensive product line covering dialysis machines, dialysis consumables, and peritoneal dialysis solutions, creating a competitive advantage that is difficult to replicate through technological synergy and scale effects [1][2] Production and Financial Performance - Weigao Blood Purification has established production bases in cities like Weihai, Chengdu, and Jiangxi, forming a nationwide capacity network supported by medical device industry cluster policies [2] - The company has implemented a cash dividend policy since its listing, distributing a total of 65.8231 million yuan in cash dividends, with the mid-2025 dividend accounting for 29.89% of the net profit during the same period [2] Future Strategy - The company plans to focus on "innovation-driven, global layout, and industry chain extension" as its three main directions, increasing R&D investment to drive core technology breakthroughs and product upgrades [2] - Weigao Blood Purification aims to deepen its market presence in Southeast Asia, South America, Eastern Europe, and North Africa, enhancing its overseas market penetration while pursuing mergers and acquisitions to expand its business boundaries and capitalize on domestic substitution opportunities [2]